8-K: ADC Therapeutics 2025 Revenue Up, Cash Runway to 2028

ADC Therapeutics announced preliminary 2025 financial results, including increased ZYNLONTA revenue and an extended cash runway, alongside key clinical trial updates.

Summary

• Preliminary unaudited ZYNLONTA net product revenue for full year 2025 is expected to be approximately $73 million, an increase from $69.3 million in full year 2024.
• Fourth quarter 2025 ZYNLONTA net product revenue is expected to be approximately $22 million, up from $16.4 million in the fourth quarter of 2024.
• The company ended 2025 with approximately $261 million in cash and cash equivalents, providing an expected cash runway at least to 2028.
• Updated data from the LOTIS-7 Phase 1b trial showed an 89.8% best overall response rate and a 77.6% complete response rate in r/r DLBCL patients.
• Complete enrollment for the LOTIS-7 trial (approximately 100 patients) is expected in the first half of 2026, with full data by the end of 2026.
• Topline data from the LOTIS-5 Phase 3 confirmatory trial in 2L+ DLBCL is anticipated in the second quarter of 2026, with full results by the end of 2026.
• Investigator-initiated trials (IITs) of ZYNLONTA in indolent lymphomas (follicular lymphoma and marginal zone lymphoma) have shown promising efficacy and manageable safety, with data publication anticipated as early as the end of 2026.
• IND-enabling activities for the company's PSMA-targeting ADC were completed at the end of 2025, and partnership opportunities are being explored.
• An acceleration in net product revenue growth is anticipated beginning in 2027, assuming positive clinical results and regulatory approvals.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook, driven by increased revenue for ZYNLONTA, a significantly extended cash runway, and promising clinical trial data for pipeline expansion. The clear roadmap for future catalysts and potential regulatory approvals further enhances the positive sentiment, indicating solid operational and strategic progress.

Positives

• Full year 2025 ZYNLONTA net product revenue increased to approximately $73 million, up from $69.3 million in 2024.
• Fourth quarter 2025 ZYNLONTA net product revenue increased to approximately $22 million, up from $16.4 million in Q4 2024.
• Cash and cash equivalents of approximately $261 million as of December 31, 2025, extend the expected cash runway at least to 2028.
• LOTIS-7 Phase 1b trial demonstrated strong efficacy with an 89.8% best overall response rate and a 77.6% complete response rate in r/r DLBCL.
• Anticipated multiple clinical catalysts in 2026, including LOTIS-7 complete enrollment and LOTIS-5 Phase 3 topline data.
• Promising initial efficacy and manageable safety results from investigator-initiated trials of ZYNLONTA in indolent lymphomas.
• Completion of IND-enabling activities for the PSMA-targeting ADC expands the pipeline and offers potential partnership opportunities.

Risks

• Preliminary unaudited Q4 and full year 2025 net product revenue and cash and cash equivalents may change.
• The expected cash runway at least to 2028 assumes the use of a minimum liquidity amount required under loan agreement covenants.
• Future LOTIS-7 clinical trial results may not be consistent with or different from previously presented data, impacting timing, publication, compendia inclusion, regulatory strategy, and commercial opportunity.
• The timing of PFS events and topline data release for LOTIS-5, as well as the trial results, sBLA submission, and full FDA approval, are subject to uncertainties.
• The company's ability to grow ZYNLONTA revenue in the United States and achieve potential peak revenue is not guaranteed.
• The ability of partners to commercialize ZYNLONTA in foreign markets, the timing and amount of future revenue and payments from partnerships, and their ability to obtain foreign regulatory approval are uncertain.
• The timing and results of the company's clinical trials, including IITs, and their potential regulatory and/or compendia strategy and future opportunity, are subject to risks.
• The timing and outcome of regulatory submissions for products or product candidates, and actions by the FDA or foreign regulatory authorities, may differ from expectations.
• Projected revenue and expenses are estimates and may not be realized.
• The company's indebtedness, including facilities with Healthcare Royalty Management, Blue Owl, and Oaktree, imposes restrictions on activities, requires compliance with terms, and significant cash for service.
• The company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities is not assured.
• Uncertainties of international trade policies, including tariffs, sanctions, trade barriers, and most favored nation drug pricing, may impact business, financial condition, and results of operations.

Future Outlook

ADC Therapeutics anticipates an acceleration in net product revenue growth beginning in 2027, driven by multiple clinical catalysts in 2026, including full results from LOTIS-5 and LOTIS-7 trials, and potentially from ongoing Phase 2 indolent lymphoma IITs. Assuming positive results, the company expects potential compendia inclusion for these programs in the first half of 2027, with LOTIS-5 regulatory approvals to follow in mid-2027. The company also continues to explore partnership opportunities for its PSMA-targeting ADC.

Management Comments

• "During 2025, we delivered meaningful progress across our ZYNLONTA clinical program and extended our expected cash runway at least to 2028."
• "This year, we look forward to multiple clinical catalysts including full results from our LOTIS-5 and LOTIS-7 2L+ DLBCL trials, as well as potentially from the ongoing Phase 2 indolent lymphoma IITs."
• "Assuming positive results, we anticipate potential compendia inclusion for each in the first half of 2027 with LOTIS-5 regulatory approvals to follow."
• "Taken together, we anticipate we will see an acceleration in net product revenue growth beginning in 2027."

Industry Context

ADC Therapeutics operates as a commercial-stage global leader in antibody drug conjugates (ADCs), a rapidly evolving area in oncology. The company's flagship product, ZYNLONTA, is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The reported updates indicate a strategic focus on expanding ZYNLONTA's market reach into earlier lines of therapy (2L+ DLBCL) and other lymphoma types (indolent lymphomas), as well as advancing a new pipeline candidate (PSMA-targeting ADC). This aligns with broader industry trends of developing targeted therapies and combination regimens to improve outcomes in difficult-to-treat cancers, leveraging the precision of ADCs.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue, extended cash runway, and a robust clinical pipeline with multiple near-term catalysts, potentially leading to future value appreciation.
• Patients: Potential for new and improved treatment options for relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma, as well as future prostate cancer therapies.
• Employees: Enhanced job security and growth opportunities within a financially stable company with a promising product pipeline.
• Creditors: Reduced risk due to a strong cash position and an extended cash runway, indicating improved ability to meet financial obligations.
• Customers (Healthcare Providers): Continued availability and potential expansion of ZYNLONTA's indications, offering more treatment choices for their patients.

Next Steps

• Complete enrollment of approximately 100 patients in the LOTIS-7 trial during the first half of 2026.
• Provide topline data from the LOTIS-5 Phase 3 confirmatory trial in the second quarter of 2026.
• Share full data from the LOTIS-7 trial at a medical meeting and through publication by the end of 2026.
• Publish full results from the LOTIS-5 trial by the end of 2026.
• Publish initial data from Phase 2 investigator-initiated trials (IITs) in follicular lymphoma and marginal zone lymphoma as early as the end of 2026.
• Assess regulatory and compendia strategies for LOTIS-7 in the first half of 2027.
• Submit a supplemental Biologics License Application (sBLA) to the U.S. FDA for LOTIS-5, assuming positive results.
• Assess regulatory and compendia strategies for IITs, assuming positive data.
• Pursue potential compendia inclusion for LOTIS-5 and LOTIS-7 in the first half of 2027.
• Seek confirmatory approval for LOTIS-5 in 2L+ DLBCL in mid-2027.
• Continue to explore partnership opportunities for the PSMA-targeting ADC.

Key Dates

Recommendation

The company reported strong preliminary revenue growth for ZYNLONTA and significantly extended its cash runway to at least 2028, which are positive indicators of financial stability and operational progress. Promising clinical data from LOTIS-7 and anticipated topline results for LOTIS-5 in 2Q 2026, along with progress in IITs and a new pipeline candidate, suggest strong future growth potential. However, the underlying demand for ZYNLONTA in its current indication remained stable, indicating that significant revenue acceleration is contingent on successful expansion into new indications and regulatory approvals, which are still 1-2 years out. Given the mix of current stability and future potential, a 'hold' recommendation is appropriate, awaiting further definitive clinical trial results and regulatory milestones before a stronger stance.

Keywords

ADC Therapeutics, ADCT, ZYNLONTA, loncastuximab tesirine-lpyl, antibody drug conjugates, DLBCL, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, r/r DLBCL, oncology, biopharma, clinical trials, revenue, cash runway, LOTIS-5, LOTIS-7, PSMA-targeting ADC, preliminary results